New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you advise mobility restrictions in a patient with Protein S deficiency and acute upper extremity DVTs but contraindications to anticoagulation (e.g., acute GI bleed) to reduce the risk of thrombus embolization?

3
1 Answers

Mednet MemberInvited Expert
General Internal Medicine · University of Chicago

This question is an interesting one and an incredibly specific scenario. I'll try to broaden the answer to cover a few more scenarios. So, the question gets at three elements: 1) Patient has an acute VTE, 2) Patient has a hypercoagulable state, 3) Patient has a contraindication to anticoagulation. S...

Do you screen children with sickle cell disease for silent cerebral infarcts?

1
2 Answers

Mednet MemberInvited Expert
Pediatric Hematology/Oncology · Nationwide Children's Hospital

We screen children with sickle cell disease for SCIs at our center. This is because data suggest that silent cerebral infarcts (SCIs) are much more common than overt stroke and the long-term negative impacts of SCIs are significant. There are also treatments (e.g., chronic transfusion and stem cell ...

What is your approach to IV fluid resuscitation during a sickle cell vaso-occlusive crisis?

2 Answers

Mednet MemberInvited Expert
General Internal Medicine · MacNeal Center

My approach to IV fluid resuscitation in vaso-occlusive crisis is cautious and individualized. Adequate hydration is important to prevent further sickling, but I avoid aggressive fluid loading because of the risks of pulmonary edema and acute chest syndrome. I typically use isotonic balanced crystal...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Is the PFS benefit sufficient to adopt up front acalabrutinib plus BR for all patients with MCL?

3 Answers

Mednet Member
Medical Oncology · Fox Chase Cancer Center

In my opinion, PFS is not sufficient to adopt BR-acala as a universal treatment, but this can be an important treatment option for many patients. I would offer the BR-acala combo in patients who value maximizing duration of treatment response, recognizing this is a continuous regimen. On the other h...

How would you work up a patient with cutaneous mastocytosis?

1
2 Answers

Mednet MemberInvited Expert
Dermatology · Duke Health

In adults, consider mastocytosis as being systemic until you prove it is not. A single normal or low-elevated tryptase does not eliminate the possibility of systemic mastocytosis. All patients should go to Heme/Onc for consideration of bone marrow biopsy and ideally high-sensitivity PCR to look for ...

Would you consider prophylactic anticoagulation for May-Thurner syndrome in pregnancy if prior endovascular intervention has been completed?

1
1 Answers

Mednet MemberInvited Expert
Hematology · University of Rochester School of Medicine and Dentistry

In general, I have a very low threshold to initiate prophylactic anticoagulation in pregnancy. For a patient with a history of May-Thurner that has been endovascularly corrected and who has been maintained off of anticoagulation without issue, I would have a risk-benefit discussion about prophylacti...

Do you use MRD testing to guide maintenance therapy discontinuation in newly diagnosed non-high risk myeloma patients?

1
3 Answers

Mednet MemberInvited Expert
Medical Oncology · University of Chicago

Major bias, incoming!The short answer is: yes, I use MRD to guide de-escalation and ultimately discontinuation in standard-risk patients with myeloma.Much of that sentiment comes from our work at the University of Chicago called MRD2STOP, where we allow patients to stop treatment if they are sustain...

How do you manage perioperative anticoagulation for a patient with a history of recent, surgically provoked VTE?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Medical University of South Carolina

In most cases, bridging is rarely indicated because the bleeding risk usually outweighs the risk of VTE recurrence during a short (1–2 day) interruption of anticoagulation. However, after a recent VTE (defined as <3 months), the estimated risk of VTE recurrence is high (>15–20% per year) (still low ...

When would you use rusfertide to treat polycythemia vera?

2 Answers

Mednet MemberInvited Expert
Hematology · University of Chicago

I think of rusfertide as being a very effective adjunctive therapy for patients with PV who are on cytoreduction and still requiring phlebotomy! Given the impact of inducing a molecular response when using a cytoreductive therapy in the treatment of PV, as has been seen across a variety of studies, ...

What tips do you provide patients on therapeutic LMWH who have difficulty with injections and are bothered by bruising?

2 Answers

Mednet MemberInvited Expert
Hematology · Gundersen Health

I counsel patients that injection site bruising is extremely common and should be expected. To try to limit the impact, they should make sure they are avoiding injection into the superficial blood vessels on either side of the abdomen. Sometimes moving to thighs or upper arms can help. If injections...